INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 411m ago
HOUSE PTR11m ago
SEC 13F10m ago
ROBINHOOD CHAIN10m ago
SEC FORM 4/Grant or awardVerified data

Bassan Abraham reported RANI

Director · Rani Therapeutics Holdings, Inc. · Rani Therapeutics Holdings, Inc. — Director Stock Option (Right to Buy)

Side
A
Value
—
Shares
123.6K
Price
—
Executed
May 28, 2026
Disclosed
Jun 1, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
May 28 executedJun 1, 2026 disclosed

RANI · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · RANI

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    JA
    Javadi AlirezaChief Technical Officer
    RANIRani Therapeutics Holdings, Inc.
    Grant or award
    		A—
    805.5K sh
    		Jun 3, 2026Jun 5, 2026
    traded Jun 3, 2026
    		+2dSEC FORM 4

    Evidence

    9
    IT
    Imran TalatDirector, Chief Executive Officer
    RANIRani Therapeutics Holdings, Inc.
    Grant or award
    		A—
    3.80M sh
    		Jun 3, 2026Jun 5, 2026
    traded Jun 3, 2026
    		+2dSEC FORM 4

    Evidence

    9
    MK
    McKinley KateChief Business Officer
    RANIRani Therapeutics Holdings, Inc.
    Grant or award
    		A—
    805.5K sh
    		Jun 3, 2026Jun 5, 2026
    traded Jun 3, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BJ
    Bailey Vasudev JaiprakashDirector
    RANIRani Therapeutics Holdings, Inc.
    Grant or award
    		A—
    123.6K sh
    		May 28, 2026Jun 1, 2026
    traded May 28, 2026
    		+4dSEC FORM 4

    Evidence

    9
    RA
    Rometty Lisa AnnDirector
    RANIRani Therapeutics Holdings, Inc.
    Grant or award
    		A—
    123.6K sh
    		May 28, 2026Jun 1, 2026
    traded May 28, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001864485-26-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    May 28, 2026
    Published
    Jun 1, 2026
    Ingested by INSIDER
    Nov 5, 03:55 UTC
    Last re-read
    Nov 5, 03:55 UTC

    Extracted facts

    Filer
    Bassan Abraham
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Rani Therapeutics Holdings, Inc. — Director Stock Option (Right to Buy)
    Ticker
    RANI
    Shares
    123.6K
    Price per share
    $0
    Execution date (reported)
    May 28, 2026
    Owned after transaction
    123.6K shares
    Days from execution to publication
    4

    What this establishes

    Bassan Abraham filed this Form 4 reporting a grant or award of RANI on May 28, 2026. It became public on Jun 1, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Bassan Abrahamcik:0001864485
    Issuer
    Rani Therapeutics Holdings, Inc.cik:0001856725

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.